Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurney, M. E.
Right arrow Articles by Hall, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurney, M. E.
Right arrow Articles by Hall, E. D.
NEUROLOGY 1998;50:62-66
© 1998 American Academy of Neurology

Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis

Mark E. Gurney, PhD, Timothy J. Fleck, BS, Carol S. Himes and Edward D. Hall, PhD

From Pharmacia Upjohn Discovery Research, Kalamazoo, MI.

Address correspondence to Mark E. Gurney, PhD, Pharmacia Upjohn Discovery Research, 301 Henrietta Street, Kalamazoo, MI 49007.

Riluzole was tested in a dose-ranging study for preservation of motor function in a transgenic mouse model of familial ALS. The model is based on expression of mutant human Cu,Zn superoxide dismutase in mouse brain and spinal cord. In contrast with the human ALS trials, in the mouse model, riluzole significantly preserved motor function as assessed by nightly running in a wheel. The effect of riluzole on motor performance was greater earlier in disease than later, suggesting that riluzole may have benefit for"quality-of-life" measures in ALS. Treatment with riluzole was initiated earlier in the transgenic model than in the human ALS trials, which may account for the significantly better outcome.

Received April 3, 1997. Accepted in final form August 1, 1997.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
P. Fanara, J. Banerjee, R. V. Hueck, M. R. Harper, M. Awada, H. Turner, K. H. Husted, R. Brandt, and M. K. Hellerstein
Stabilization of Hyperdynamic Microtubules Is Neuroprotective in Amyotrophic Lateral Sclerosis
J. Biol. Chem., August 10, 2007; 282(32): 23465 - 23472.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. Rouaux, I. Panteleeva, F. Rene, J.-L. Gonzalez de Aguilar, A. Echaniz-Laguna, L. Dupuis, Y. Menger, A.-L. Boutillier, and J.-P. Loeffler
Sodium Valproate Exerts Neuroprotective Effects In Vivo through CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model
J. Neurosci., May 23, 2007; 27(21): 5535 - 5545.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. B. Choudry and M. E. Cudkowicz
Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future
J. Clin. Pharmacol., December 1, 2005; 45(12): 1334 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Tateno, H. Sadakata, M. Tanaka, S. Itohara, R.-M. Shin, M. Miura, M. Masuda, T. Aosaki, M. Urushitani, H. Misawa, et al.
Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model
Hum. Mol. Genet., October 1, 2004; 13(19): 2183 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Cassiman, M. Thomeer, E. Verbeken, and W. Robberecht
Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS
Neurology, October 28, 2003; 61(8): 1150 - 1151.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. D. Ghadge, B. S. Slusher, A. Bodner, M. D. Canto, K. Wozniak, A. G. Thomas, C. Rojas, T. Tsukamoto, P. Majer, R. J. Miller, et al.
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models
PNAS, August 5, 2003; 100(16): 9554 - 9559.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Canton, G. A. Bohme, A. Boireau, F. Bordier, S. Mignani, P. Jimonet, G. Jahn, M. Alavijeh, J. Stygall, S. Roberts, et al.
RPR 119990, a Novel alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Antagonist: Synthesis, Pharmacological Properties, and Activity in an Animal Model of Amyotrophic Lateral Sclerosis
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 314 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. Li, V. O. Ona, C. Guégan, M. Chen, V. Jackson-Lewis, L. J. Andrews, A. J. Olszewski, P. E. Stieg, J. Lee, S. Przedborski, et al.
Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model
Science, April 14, 2000; 288(5464): 335 - 339.
[Abstract] [Full Text]

Home page
 NeurologyHome page
M. D. Caramia, M. G. Palmieri, M. T. Desiato, C. Iani, A. Scalise, S. Telera, and G. Bernardi
Pharmacologic reversal of cortical hyperexcitability in patients with ALS
Neurology, January 11, 2000; 54(1): 58 - 58.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
R. G. Miller
Clinical Trials in Motor Neuron Diseases
J Child Neurol, March 1, 1999; 14(3): 173 - 179.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.